Non Small Cell Clinical Trials in Barcelona
8 recruitingBarcelona, Spain
Showing 1–8 of 8 trials
Recruiting
Phase 3
Study to Evaluate Efficacy and Safety of Firmonertinib Compared With Investigator's Choice of EGFR Inhibitor as First-Line Treatment in Participants Who Have Locally Advanced or Metastatic NSCLC With EGFR P-Loop and Alpha C-Helix Compressing (PACC) Uncommon Mutations
Non-small Cell Lung CancerAdvanced Non-Small Cell Lung CancerMetastatic Non Small Cell Lung Cancer+3 more
ArriVent BioPharma, Inc.480 enrolled62 locationsNCT07185997
Recruiting
Phase 1
A Study of ZW251 in Participants With Advanced Solid Tumors
Hepatocellular CarcinomaGerm Cell TumorSquamous Cell Non Small Cell Lung Cancer
Zymeworks BC Inc.100 enrolled25 locationsNCT07164313
Recruiting
Phase 1
Open-label Study of BBO-8520 in Adult Subjects With KRASG12C Non-small Cell Lung Cancer
Non-small Cell Lung CancerMetastatic Lung CancerNSCLC+3 more
TheRas, Inc., d/b/a BBOT (BridgeBio Oncology Therapeutics)350 enrolled35 locationsNCT06343402
Recruiting
Phase 2
Autologous LN-145 in Patients With Metastatic Non-Small-Cell Lung Cancer
Metastatic Non Small Cell Lung Cancer
Iovance Biotherapeutics, Inc.170 enrolled91 locationsNCT04614103
Recruiting
Phase 2Phase 3
Phase 2 Trial of Adagrasib Monotherapy and in Combination With Pembrolizumab and a Phase 3 Trial of Adagrasib in Combination in Patients With a KRAS G12C Mutation KRYSTAL-7
Advanced Non-Small Cell Lung CancerMetastatic Non Small Cell Lung Cancer
Mirati Therapeutics Inc.806 enrolled764 locationsNCT04613596
Recruiting
Phase 3
A Study to Investigate the Efficacy and Safety of Dato-DXd With or Without Osimertinib Compared With Platinum Based Doublet Chemotherapy in Participants With EGFR-Mutated Locally Advanced or Metastatic Non-Small Cell Lung Cancer
Metastatic Non Small Cell Lung Cancer
AstraZeneca744 enrolled302 locationsNCT06417814
Recruiting
Phase 3
Study of Dato-DXd Plus Pembrolizumab vs Pembrolizumab Alone in the First-line Treatment of Subjects With Advanced or Metastatic NSCLC Without Actionable Genomic Alterations
Metastatic Non Small Cell Lung Cancer
Daiichi Sankyo740 enrolled243 locationsNCT05215340
Recruiting
Phase 3
LUNAR-2: TTFields With Pembrolizumab + Platinum-based Chemotherapy for Metastatic NSCLC
Metastatic Non Small Cell Lung Cancer
NovoCure GmbH734 enrolled90 locationsNCT06216301